Nuformix’s innovative clinical pipeline is based on cocrystal forms of existing drugs. This allows re-use of existing safety data, reducing the time and cost of achieving clinical proof-of-concept and increasing success rates versus traditional biotech models.

Nuformix’s will continue to progress its development pipeline and IP portfolio. Pre-clinical validation will support future entries to the clinical pipeline.